Savara (NSDQ:SVRA) announced today that it priced an underwritten public offering of common stock at approximately $113 million. Austin, Texas–based Savara — an orphan lung disease treatment company with an inhaled formulation of recombinant human GM-CSF — is offering nearly 45.8 million shares of its common stock to the public at a price of $1.45 per […]
Funding Roundup
Xeris Pharmaceuticals prices $27M offering
Xeris Pharmaceuticals (NSDQ:XERS) announced today that it priced a registered direct offering of common stock at $27 million. Chicago-based Xeris is offering nearly 6.6 million shares of common stock to funds managed by Deerfield Management Company, which are existing investors in the company, according to a news release. Xeris develops technology platforms to enable ready-to-use, room-temperature […]
Neurelis closes $114M Series D for diazepam nasal spray
Neurelis announced today that it closed a $114 million Series D financing round to support its lead orphan drug product. San Diego-based Neurelis’ Valtoco (diazepam nasal spray) is a proprietary formulation incorporating the science of Intravail transmucosal absorption enhancement technology. The drug enables the noninvasive delivery of a range of drugs, while the company focuses on […]
ForSight Robotics raises $10M for ophthalmic robotic surgery platform
Forsight Robotics, a developer of a robotic surgical platform for ophthalmic procedures, has reportedly raised $10 million. According to a report from TechCrunch, the seed round of financing was led by Eclipse Ventures and Mithril Capital and is earmarked to be used for expanding the company’s headcount and global reach as it sets its sights […]
Henry Schein reinstates share repurchase program
Henry Schein (NSDQ:HSIC) announced today that it entered into amendments to reinstate its share repurchase program. Melville, N.Y.-based Henry Schein’s amendments to its private placement facility permit the company to reinstate the share repurchase program, according to a news release. The company said it had $201 million authorized and available for future stock repurchases at the […]
Private equity firm GTCR forms Epselon Global to acquire healthcare businesses
GTCR announced that it entered into a Leaders Strategy partnership to form Epselon Global to acquire healthcare businesses. The private equity firm partnered with Michael Mulhern and Phil Macnabb to form the Chicago-based company centered around acquiring companies and assets as part of a strategy to build a market-leading healthcare business, according to a news […]
Pulmatrix completes $40M offering, updates product pipeline timetable
Pulmatrix (NSDQ:PULM) announced today that it completed an offering with gross proceeds of approximately $40 million. Lexington, Mass.-based Pulmatrix said in a news release that it completed the registered direct offering to extend the company’s cash runway. Now, the company has additional financing to help fully fund data readouts across its development pipeline, which includes […]
PLx Pharma prices $63M offering
PLx Pharma (NSDQ:PLXP) announced today that it priced an underwritten public offering worth approximately $63 million. Sparta, N.J.–based PLx Pharma is offering 7.875 million shares of its common stock priced at $8 per share to the public, according to a news release. Get the full story at our sister site, Drug Delivery Business News.
MedTech 100 Roundup: Small slide continues
On the back of several weeks of new records and strong performances, the medtech industry has finally hit a snag in its recent ascent. MassDevice‘s MedTech 100 index ended the week (Feb. 26) at 106.65 points, marking a 1.9% dip from the 108.72-point mark set one week before (Feb. 19). This highlights a similar drop from […]
ReWalk Robotics closes $40M private placement
ReWalk Robotics (NSDQ:RWLK) announced today that it closed a private placement worth approximately $40 million. Marlborough, Mass.-based Rewalk Robotics’ private placement included more than 10.9 million ordinary shares and warrants to purchase up to nearly 5.5 million ordinary shares at a purchase price of $3.6625 per share and associated warrant, according to a news release. […]
NuVasive reports mixed Q4 results
NuVasive (NASDAQ: NUVA) today reported Q4 earnings that beat the consensus forecast on Wall Street, but it came up short on revenue. The San Diego–based spine tech company earned $1.7 million, or 3¢ per share, on sales of $291.8 million for the three months ended Dec. 31, 2020, for a bottom-line drop of –94% on […]
